Indeed, RET testing is currently used in routine in next-generation sequencing (NGS) panels, which identified 2% of RET alterations in various types of cancer, including digestive, breast, ovarian, and head-and-neck cancers (6). This evidence concerns the gene RET and head and neck cancer.